+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Non-small Cell Lung Cancer Therapeutics Market Research Report by Cancer Type, Drug Class, Distribution Channel, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19

  • ID: 4968594
  • Report
  • April 2022
  • Region: Global
  • 215 Pages
  • 360iResearch™
UP TO OFF until Dec 31st 2022

FEATURED COMPANIES

  • Astellas Pharma Inc
  • Bristol Myers Squibb
  • Eisai Co., Ltd
  • F. Hoffmann-La Roche Ltd
  • Merck KGaA
  • Orion Corporation
The Global Non-small Cell Lung Cancer Therapeutics Market size was estimated at USD 14.40 billion in 2021, USD 15.48 billion in 2022, and is projected to grow at a Compound Annual Growth Rate (CAGR) of 7.66% to reach USD 22.43 billion by 2027.



Market Statistics:


The report provides market sizing and forecast across five major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2019 and 2020 are considered historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered the forecast period.

Market Segmentation & Coverage:


This research report categorizes the Non-small Cell Lung Cancer Therapeutics to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Cancer Type, the market was studied across Adenocarcinoma, Large Cell Carcinoma, and Squamous Cell Carcinoma.
  • Based on Drug Class, the market was studied across Angiogenesis Inhibitor, Epidermal Growth Factor Receptor Blocker, Folate Antimetabolites, Kinase Inhibitor, Microtubule Stabilizer, and PD-1/ PD-L1 Inhibitor.
  • Based on Distribution Channel, the market was studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, and Thailand. Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:


COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Cumulative Impact of 2022 Russia Ukraine Conflict:


We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.

This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Non-small Cell Lung Cancer Therapeutics market considering the current update on the conflict and its global response.

Competitive Strategic Window:


The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:


The FPNV Positioning Matrix evaluates and categorizes the vendors in the Non-small Cell Lung Cancer Therapeutics Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:


The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:


The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:


The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Non-small Cell Lung Cancer Therapeutics Market, including Astellas Pharma Inc, AstraZeneca PLC, Bristol Myers Squibb, C.H. Boehringer Sohn AG & Ko. KG, Celgene Corporation, Eisai Co., Ltd, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline PLC, Merck KGaA, Novartis International AG, Orion Corporation, Pfizer Inc, Sanofi S.A., and Takeda Pharmaceutical Company Limited.

The report provides insights on the following pointers:


1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:


1. What is the market size and forecast of the Global Non-small Cell Lung Cancer Therapeutics Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Non-small Cell Lung Cancer Therapeutics Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Non-small Cell Lung Cancer Therapeutics Market?
4. What is the competitive strategic window for opportunities in the Global Non-small Cell Lung Cancer Therapeutics Market?
5. What are the technology trends and regulatory frameworks in the Global Non-small Cell Lung Cancer Therapeutics Market?
6. What is the market share of the leading vendors in the Global Non-small Cell Lung Cancer Therapeutics Market?
7. What modes and strategic moves are considered suitable for entering the Global Non-small Cell Lung Cancer Therapeutics Market?
Frequently Asked Questions about the Global Non-small Cell Lung Cancer Therapeutics Market

What is the estimated value of the Global Non-small Cell Lung Cancer Therapeutics Market?

The Global Non-small Cell Lung Cancer Therapeutics Market was estimated to be valued at $14.4 Billion in 2021.

What is the growth rate of the Global Non-small Cell Lung Cancer Therapeutics Market?

The growth rate of the Global Non-small Cell Lung Cancer Therapeutics Market is 7.6%, with an estimated value of $22.4 Billion by 2027.

What is the forecasted size of the Global Non-small Cell Lung Cancer Therapeutics Market?

The Global Non-small Cell Lung Cancer Therapeutics Market is estimated to be worth $22.4 Billion by 2027.

Who are the key companies in the Global Non-small Cell Lung Cancer Therapeutics Market?

Key companies in the Global Non-small Cell Lung Cancer Therapeutics Market include Astellas Pharma Inc, AstraZeneca PLC, Bristol Myers Squibb, C.H. Boehringer Sohn AG & Ko. KG, Celgene Corporation, Eisai Co., Ltd, Eli Lilly and Company, F. Hoffmann and GlaxoSmithKline PLC.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Astellas Pharma Inc
  • Bristol Myers Squibb
  • Eisai Co., Ltd
  • F. Hoffmann-La Roche Ltd
  • Merck KGaA
  • Orion Corporation

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of Non-small Cell Lung Cancer (NSCLC) across the globe due to increasing air pollution and smoking habits
5.1.1.2. Presence of a strong pipeline for NSCLC therapeutics
5.1.2. Restraints
5.1.2.1. High cost and lack of availability of the drug
5.1.3. Opportunities
5.1.3.1. Introduction of new targeted therapies and treatments
5.1.3.2. Adoption of advanced therapeutics in the developing countries
5.1.4. Challenges
5.1.4.1. Capital intensive treatment and procedures
5.2. Cumulative Impact of COVID-19
5.3. Cumulative Impact of 2022 Russia Ukraine Conflict
6. Non-small Cell Lung Cancer Therapeutics Market, by Cancer Type
6.1. Introduction
6.2. Adenocarcinoma
6.3. Large Cell Carcinoma
6.4. Squamous Cell Carcinoma
7. Non-small Cell Lung Cancer Therapeutics Market, by Drug Class
7.1. Introduction
7.2. Angiogenesis Inhibitor
7.3. Epidermal Growth Factor Receptor Blocker
7.4. Folate Antimetabolites
7.5. Kinase Inhibitor
7.6. Microtubule Stabilizer
7.7. PD-1/ PD-L1 Inhibitor
8. Non-small Cell Lung Cancer Therapeutics Market, by Distribution Channel
8.1. Introduction
8.2. Hospital Pharmacies
8.3. Online Pharmacies
8.4. Retail Pharmacies
9. Americas Non-small Cell Lung Cancer Therapeutics Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Non-small Cell Lung Cancer Therapeutics Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
11. Europe, Middle East & Africa Non-small Cell Lung Cancer Therapeutics Market
11.1. Introduction
11.2. France
11.3. Germany
11.4. Italy
11.5. Netherlands
11.6. Qatar
11.7. Russia
11.8. Saudi Arabia
11.9. South Africa
11.10. Spain
11.11. United Arab Emirates
11.12. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion
13. Company Usability Profiles
13.1. Astellas Pharma Inc
13.2. AstraZeneca PLC
13.3. Bristol Myers Squibb
13.4. C.H. Boehringer Sohn AG & Ko. KG
13.5. Celgene Corporation
13.6. Eisai Co., Ltd
13.7. Eli Lilly and Company
13.8. F. Hoffmann-La Roche Ltd
13.9. GlaxoSmithKline PLC
13.10. Merck KGaA
13.11. Novartis International AG
13.12. Orion Corporation
13.13. Pfizer Inc
13.14. Sanofi S.A.
13.15. Takeda Pharmaceutical Company Limited
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing
List of Figures
FIGURE 1. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET: DYNAMICS
FIGURE 2. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2021 VS 2027 (%)
FIGURE 3. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2021 VS 2027 (USD BILLION)
FIGURE 4. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2027
FIGURE 5. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ADENOCARCINOMA, 2019-2027 (USD BILLION)
FIGURE 6. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ADENOCARCINOMA, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 7. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LARGE CELL CARCINOMA, 2019-2027 (USD BILLION)
FIGURE 8. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LARGE CELL CARCINOMA, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 9. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SQUAMOUS CELL CARCINOMA, 2019-2027 (USD BILLION)
FIGURE 10. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SQUAMOUS CELL CARCINOMA, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 11. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2021 VS 2027 (%)
FIGURE 12. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2021 VS 2027 (USD BILLION)
FIGURE 13. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2027
FIGURE 14. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ANGIOGENESIS INHIBITOR, 2019-2027 (USD BILLION)
FIGURE 15. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ANGIOGENESIS INHIBITOR, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 16. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EPIDERMAL GROWTH FACTOR RECEPTOR BLOCKER, 2019-2027 (USD BILLION)
FIGURE 17. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EPIDERMAL GROWTH FACTOR RECEPTOR BLOCKER, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 18. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FOLATE ANTIMETABOLITES, 2019-2027 (USD BILLION)
FIGURE 19. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FOLATE ANTIMETABOLITES, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 20. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY KINASE INHIBITOR, 2019-2027 (USD BILLION)
FIGURE 21. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY KINASE INHIBITOR, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 22. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY MICROTUBULE STABILIZER, 2019-2027 (USD BILLION)
FIGURE 23. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY MICROTUBULE STABILIZER, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 24. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1/ PD-L1 INHIBITOR, 2019-2027 (USD BILLION)
FIGURE 25. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1/ PD-L1 INHIBITOR, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 26. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2021 VS 2027 (%)
FIGURE 27. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2021 VS 2027 (USD BILLION)
FIGURE 28. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2027
FIGURE 29. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, 2019-2027 (USD BILLION)
FIGURE 30. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 31. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, 2019-2027 (USD BILLION)
FIGURE 32. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 33. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, 2019-2027 (USD BILLION)
FIGURE 34. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 35. AMERICAS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 36. ARGENTINA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 37. BRAZIL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 38. CANADA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 39. MEXICO NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 40. UNITED STATES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 41. ASIA-PACIFIC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 42. AUSTRALIA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 43. CHINA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 44. INDIA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 45. INDONESIA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 46. JAPAN NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 47. MALAYSIA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 48. PHILIPPINES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 49. SINGAPORE NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 50. SOUTH KOREA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 51. TAIWAN NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 52. THAILAND NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 53. EUROPE, MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 54. FRANCE NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 55. GERMANY NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 56. ITALY NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 57. NETHERLANDS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 58. QATAR NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 59. RUSSIA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 60. SAUDI ARABIA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 61. SOUTH AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 62. SPAIN NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 63. UNITED ARAB EMIRATES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 64. UNITED KINGDOM NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 65. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET: FPNV POSITIONING MATRIX
FIGURE 66. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET: SHARE, BY KEY PLAYER, 2021
FIGURE 67. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET, BY TYPE
List of Tables
TABLE 1. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET: MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016–2020
TABLE 3. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2019-2027 (USD BILLION)
TABLE 4. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ADENOCARCINOMA, BY REGION, 2019-2027 (USD BILLION)
TABLE 5. AMERICAS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ADENOCARCINOMA, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 6. UNITED STATES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ADENOCARCINOMA, BY STATE, 2019-2027 (USD BILLION)
TABLE 7. ASIA-PACIFIC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ADENOCARCINOMA, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 8. EUROPE, MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ADENOCARCINOMA, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 9. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LARGE CELL CARCINOMA, BY REGION, 2019-2027 (USD BILLION)
TABLE 10. AMERICAS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LARGE CELL CARCINOMA, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 11. UNITED STATES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LARGE CELL CARCINOMA, BY STATE, 2019-2027 (USD BILLION)
TABLE 12. ASIA-PACIFIC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LARGE CELL CARCINOMA, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 13. EUROPE, MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LARGE CELL CARCINOMA, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 14. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SQUAMOUS CELL CARCINOMA, BY REGION, 2019-2027 (USD BILLION)
TABLE 15. AMERICAS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SQUAMOUS CELL CARCINOMA, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 16. UNITED STATES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SQUAMOUS CELL CARCINOMA, BY STATE, 2019-2027 (USD BILLION)
TABLE 17. ASIA-PACIFIC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SQUAMOUS CELL CARCINOMA, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 18. EUROPE, MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SQUAMOUS CELL CARCINOMA, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 19. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2019-2027 (USD BILLION)
TABLE 20. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ANGIOGENESIS INHIBITOR, BY REGION, 2019-2027 (USD BILLION)
TABLE 21. AMERICAS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ANGIOGENESIS INHIBITOR, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 22. UNITED STATES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ANGIOGENESIS INHIBITOR, BY STATE, 2019-2027 (USD BILLION)
TABLE 23. ASIA-PACIFIC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ANGIOGENESIS INHIBITOR, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 24. EUROPE, MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ANGIOGENESIS INHIBITOR, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 25. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EPIDERMAL GROWTH FACTOR RECEPTOR BLOCKER, BY REGION, 2019-2027 (USD BILLION)
TABLE 26. AMERICAS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EPIDERMAL GROWTH FACTOR RECEPTOR BLOCKER, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 27. UNITED STATES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EPIDERMAL GROWTH FACTOR RECEPTOR BLOCKER, BY STATE, 2019-2027 (USD BILLION)
TABLE 28. ASIA-PACIFIC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EPIDERMAL GROWTH FACTOR RECEPTOR BLOCKER, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 29. EUROPE, MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EPIDERMAL GROWTH FACTOR RECEPTOR BLOCKER, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 30. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FOLATE ANTIMETABOLITES, BY REGION, 2019-2027 (USD BILLION)
TABLE 31. AMERICAS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FOLATE ANTIMETABOLITES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 32. UNITED STATES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FOLATE ANTIMETABOLITES, BY STATE, 2019-2027 (USD BILLION)
TABLE 33. ASIA-PACIFIC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FOLATE ANTIMETABOLITES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 34. EUROPE, MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FOLATE ANTIMETABOLITES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 35. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY KINASE INHIBITOR, BY REGION, 2019-2027 (USD BILLION)
TABLE 36. AMERICAS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY KINASE INHIBITOR, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 37. UNITED STATES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY KINASE INHIBITOR, BY STATE, 2019-2027 (USD BILLION)
TABLE 38. ASIA-PACIFIC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY KINASE INHIBITOR, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 39. EUROPE, MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY KINASE INHIBITOR, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 40. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY MICROTUBULE STABILIZER, BY REGION, 2019-2027 (USD BILLION)
TABLE 41. AMERICAS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY MICROTUBULE STABILIZER, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 42. UNITED STATES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY MICROTUBULE STABILIZER, BY STATE, 2019-2027 (USD BILLION)
TABLE 43. ASIA-PACIFIC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY MICROTUBULE STABILIZER, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 44. EUROPE, MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY MICROTUBULE STABILIZER, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 45. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1/ PD-L1 INHIBITOR, BY REGION, 2019-2027 (USD BILLION)
TABLE 46. AMERICAS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1/ PD-L1 INHIBITOR, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 47. UNITED STATES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1/ PD-L1 INHIBITOR, BY STATE, 2019-2027 (USD BILLION)
TABLE 48. ASIA-PACIFIC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1/ PD-L1 INHIBITOR, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 49. EUROPE, MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1/ PD-L1 INHIBITOR, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 50. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD BILLION)
TABLE 51. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2019-2027 (USD BILLION)
TABLE 52. AMERICAS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 53. UNITED STATES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY STATE, 2019-2027 (USD BILLION)
TABLE 54. ASIA-PACIFIC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 55. EUROPE, MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 56. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2019-2027 (USD BILLION)
TABLE 57. AMERICAS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 58. UNITED STATES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY STATE, 2019-2027 (USD BILLION)
TABLE 59. ASIA-PACIFIC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 60. EUROPE, MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 61. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2019-2027 (USD BILLION)
TABLE 62. AMERICAS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 63. UNITED STATES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY STATE, 2019-2027 (USD BILLION)
TABLE 64. ASIA-PACIFIC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 65. EUROPE, MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 66. AMERICAS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 67. ARGENTINA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 68. BRAZIL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 69. CANADA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 70. MEXICO NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 71. UNITED STATES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 72. ASIA-PACIFIC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 73. AUSTRALIA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 74. CHINA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 75. INDIA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 76. INDONESIA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 77. JAPAN NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 78. MALAYSIA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 79. PHILIPPINES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 80. SINGAPORE NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 81. SOUTH KOREA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 82. TAIWAN NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 83. THAILAND NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 84. EUROPE, MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 85. FRANCE NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 86. GERMANY NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 87. ITALY NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 88. NETHERLANDS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 89. QATAR NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 90. RUSSIA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 91. SAUDI ARABIA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 92. SOUTH AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 93. SPAIN NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 94. UNITED ARAB EMIRATES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 95. UNITED KINGDOM NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 96. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET: SCORES
TABLE 97. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET: BUSINESS STRATEGY
TABLE 98. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET: PRODUCT SATISFACTION
TABLE 99. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET: RANKING
TABLE 100. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET: SHARE, BY KEY PLAYER, 2021
TABLE 101. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET: MERGER & ACQUISITION
TABLE 102. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 103. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 104. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET: INVESTMENT & FUNDING
TABLE 105. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 106. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET: LICENSE & PRICING
Note: Product cover images may vary from those shown
  • Astellas Pharma Inc
  • AstraZeneca PLC
  • Bristol Myers Squibb
  • C.H. Boehringer Sohn AG & Ko. KG
  • Celgene Corporation
  • Eisai Co., Ltd
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline PLC
  • Merck KGaA
  • Novartis International AG
  • Orion Corporation
  • Pfizer Inc
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
Note: Product cover images may vary from those shown

Loading
LOADING...